U.S. Markets open in 6 hrs 8 mins
  • S&P Futures

    3,784.25
    -19.00 (-0.50%)
     
  • Dow Futures

    30,232.00
    -133.00 (-0.44%)
     
  • Nasdaq Futures

    11,578.00
    -62.75 (-0.54%)
     
  • Russell 2000 Futures

    1,769.50
    -12.00 (-0.67%)
     
  • Crude Oil

    86.58
    +0.06 (+0.07%)
     
  • Gold

    1,732.40
    +1.90 (+0.11%)
     
  • Silver

    20.97
    -0.13 (-0.61%)
     
  • EUR/USD

    0.9961
    -0.0025 (-0.2490%)
     
  • 10-Yr Bond

    3.6170
    0.0000 (0.00%)
     
  • Vix

    29.07
    -1.03 (-3.42%)
     
  • GBP/USD

    1.1441
    -0.0034 (-0.2952%)
     
  • USD/JPY

    144.4000
    +0.2010 (+0.1394%)
     
  • BTC-USD

    20,232.54
    +353.82 (+1.78%)
     
  • CMC Crypto 200

    458.69
    +13.26 (+2.98%)
     
  • FTSE 100

    7,051.20
    -35.26 (-0.50%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

Odonate Announces Expected Delisting of Its Stock

·1 min read

NEW YORK, January 07, 2022--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate’s securities from listing and registration on The Nasdaq Stock Market. Additionally, Odonate intends to file with the SEC a Form 15 requesting the suspension of the Company’s reporting obligations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005100/en/

Contacts

Odonate Therapeutics, Inc.
Michael Hearne
Chief Financial Officer
(332) 208-7611
mhearne@odonate.com